Trials / Completed
CompletedNCT01840410
Assess the Efficacy/Safety of Intravitreal Ranibizumab in Patients With Vision Loss Due to Choroidal Neovascularization.
A 12-month, Randomized, Double-masked, Sham-controlled, Multicenter Study to Evaluate the Efficacy and Safety of 0.5mg Ranibizumab Intravitreal Injections in Patients With Visual Impairment Due to Vascular Endothelial Growth Factor (VEGF) Driven Choroidal Neovascularization.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 183 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
This study was conducted to evaluate the efficacy and safety of 0.5 mg ranibizumab in adult and adolescent patients with visual impairment due to choridal neovascularization (CNV).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ranibizumab | Ranibizumab 0.5mg/0.5mL was administered intravitreally to the participant. |
| OTHER | Sham control | The sham vial did not contain active drug (empty sterile vial). The sham injection was an imitation of an intravitreal injection using an injection syringe without a needle touching the eye. |
Timeline
- Start date
- 2013-09-01
- Primary completion
- 2015-11-01
- Completion
- 2015-11-01
- First posted
- 2013-04-25
- Last updated
- 2016-08-26
- Results posted
- 2016-08-26
Locations
59 sites across 21 countries: Australia, Canada, Czechia, Denmark, France, Germany, Greece, Hungary, Italy, Latvia, Lithuania, Peru, Poland, Portugal, Russia, Singapore, Slovakia, South Korea, Spain, Switzerland, Turkey (Türkiye)
Source: ClinicalTrials.gov record NCT01840410. Inclusion in this directory is not an endorsement.